Portal de Periódicos da CAPES

Significance of intracellular arsenic trioxide for therapeutic response in acute promyelocytic leukemia

2005; Wiley; Volume: 78; Issue: 2 Linguagem: Inglês

10.1002/ajh.20235

1096-8652

Geeta Sahu, Rabindra Kumar Jena,

Antioxidant Activity and Oxidative Stress

American Journal of HematologyVolume 78, Issue 2 p. 113-116 Original ArticleFree Access Significance of intracellular arsenic trioxide for therapeutic response in acute promyelocytic leukemia Geeta Ram Sahu, Corresponding Author Geeta Ram Sahu [email protected] Molecular Oncology Division, Institute of Life Sciences, Nalco Square, Chandrasekharpur, Bhubaneswar, IndiaInstitute of Life Sciences, Nalco Square, Chandrasekharpur, Bhubaneswar 751023, IndiaSearch for more papers by this authorRabindra Kumar Jena, Rabindra Kumar Jena Department of Clinical Haematology, SCB Medical College Hospital, Cuttack, Orissa, IndiaSearch for more papers by this author Geeta Ram Sahu, Corresponding Author Geeta Ram Sahu [email protected] Molecular Oncology Division, Institute of Life Sciences, Nalco Square, Chandrasekharpur, Bhubaneswar, IndiaInstitute of Life Sciences, Nalco Square, Chandrasekharpur, Bhubaneswar 751023, IndiaSearch for more papers by this authorRabindra Kumar Jena, Rabindra Kumar Jena Department of Clinical Haematology, SCB Medical College Hospital, Cuttack, Orissa, IndiaSearch for more papers by this author First published: 28 January 2005 https://doi.org/10.1002/ajh.20235Citations: 15AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat Abstract Arsenic trioxide (As2O3) is an effective drug for treatment of acute promyelocytic leukemia (APL) and malignant tumors. However, it is not commonly known to researchers that sensitivity has been associated with As2O3 concentration in target cells. Cell lines and cell strains of leukemia and solid cancer cells were treated with different concentrations of As2O3, and the concentrations were compared to apoptosis detected by FITC–annexin V and propidium iodide (PI) double staining. Results showed that intracellular and intercellular concentrations of arsenic in different cell lines differed. Our study noted that the cell lines had concentrations of arsenic trioxide in decreasing order, as follows: APL primary cell > K562 > CML primary cell > HL-60 > AML-M2 primary cell > HeLa > H-22. Higher intracellular As2O3 concentrations in cell lines APL, NB4, and K562 can be obtained by treating in culture medium with lower As2O3 concentration for longer times than the transient higher concentration. These results indicate that different leukemia and solid carcinoma cell lines have different intracellular arsenic concentrations, which correlate with different sensitivities to As2O3 in clinical treatment. The intracellular As2O3 concentration is higher; in addition, we note apoptosis, a very important observation in our study. As2O3 inhibited the growth of these cell lines significantly. Novel techniques by maintaining continuous low but effective arsenic levels inside the target leukemic cells in APL may improve the complete remission rate and overall survival with minimum cost and drug toxicity. Am. J. Hematol. 78:113–116, 2005. © 2005 Wiley-Liss, Inc. REFERENCES 1McCafferty-Grad J, Bahlis NJ, Krett N, et al. Arsenic trioxide uses caspase-dependent and caspase-independent death pathways in myeloma cells. Mol Cancer Ther 2003; 2(11): 1155–1164. CASPubMedWeb of Science®Google Scholar 2Konzawa T, Kondo Y, Ito H, Kondo S, Germano I. Induction of autophagic cell death in malignant glioma cells by arsenic trioxide. Cancer Res 2003; 63(9): 2103–2108. PubMedWeb of Science®Google Scholar 3Kito M, Matsumoto K, Sera K, et al. Anti-tumor effect of arsenic oxide in murine xenograft model. Cancer Sci 2003; 94(11): 1010–1014. 10.1111/j.1349-7006.2003.tb01393.x CASPubMedWeb of Science®Google Scholar 4Soignet SL, Maslak P, Wang ZG. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 1998; 339: 1341. 10.1056/NEJM199811053391901 CASPubMedWeb of Science®Google Scholar 5Shen ZY, Shen WY, Chen MH. Reactive oxygen species and antioxidants in apoptosis of esophageal cancer cells induced by As2O3. Int J Mol Med 2003; 11(4): 479–484. CASPubMedWeb of Science®Google Scholar 6Alemany M, Levin J. The effects of arsenic trioxide (As2O3) on human megakaryocytic leukemia cell lines. With a comparison of its effects on other cell lineages. Leuk Lymphoma 2000; 38(1–2): 153–163. CASPubMedWeb of Science®Google Scholar 7Li D, Du C, Lin Y, Wu M. Inhibition of growth of human nasopharyngeal cancer engrafts in SCID mice by arsenic trioxide. Tumor 2002; 88(6): 522–526. CASWeb of Science®Google Scholar 8Kitamura K, Minami Y, Yamamoto K. Involvement of CD95-independent caspase 8 activation in arsenic trioxide-induced apoptosis. Leukemia 2000; 14(10): 1743–1750. 10.1038/sj.leu.2401900 CASPubMedWeb of Science®Google Scholar 9Shen Y, Shen ZX, Yan H. Studies on the clinical efficacy and pharmacokinetics of low-dose arsenic trioxide in the treatment of relapsed acute promyelocytic leukemia: a comparison with conventional dosage. Leukemia 2001; 15(5): 735–741. 10.1038/sj.leu.2402106 CASPubMedWeb of Science®Google Scholar 10Zhu J, Okumura H, Ohtake S, Nakamura S, Nakao S. The molecular mechanism of arsenic trioxide-induced apoptosis and oncosis in leukemia/lymphoma cell lines. Acta Haematol 2003 ; 110(1): 1–10. 10.1159/000072407 CASPubMedWeb of Science®Google Scholar 11McCabe MJ Jr, Singh KP, Reddy SA, et al. Sensitivity of myelomonocytic leukemia cells to arsenite-induced cell cycle disruption, apoptosis, and enhanced differentiation is dependent on the inter-relationship between arsenic concentration, duration of treatment, and cell cycle phase. J Pharmacol Exp Ther 2000; 295(2): 724–733. CASPubMedWeb of Science®Google Scholar Citing Literature Volume78, Issue2February 2005Pages 113-116 ReferencesRelatedInformation